Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue 5
Submit an article Journal homepage
616
Views
10
CrossRef citations to date
0
Altmetric
Respiratory

Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting

Katherine B. WinfreeEli Lilly and Company, Indianapolis, IN, USA; Correspondence[email protected]
,
Aracelis Z. TorresFlatiron Health, New York, NY, USA
,
Yajun Emily ZhuEli Lilly and Company, Indianapolis, IN, USA;
,
Catherine MuehlenbeinEli Lilly and Company, Indianapolis, IN, USA;
,
Himani AggarwalEli Lilly and Company, Indianapolis, IN, USA;
,
Susan WoodsEli Lilly and Company, Indianapolis, IN, USA;
&
Amy AbernethyFlatiron Health, New York, NY, USA
 show all
Pages 817-827 | Received 04 May 2018, Accepted 07 Nov 2018, Published online: 10 Dec 2018

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Wang Chun Kwok, David Chi Leung Lam, Ka Yan Chiang, James Chung Man Ho, Mary Sau Man Ip & Terence Chi Chun Tam. (2020) Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma. Journal of Chemotherapy 32:8, pages 429-436.
Read now

Articles from other publishers (9)

Rossybelle Amorrortu, Melany Garcia, Yayi Zhao, Issam El Naqa, Yoganand Balagurunathan, Dung-Tsa Chen, Thanh Thieu, Matthew B Schabath & Dana E Rollison. (2023) Overview of approaches to estimate real-world disease progression in lung cancer. JNCI Cancer Spectrum 7:6.
Crossref
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip & Terence Chi Chun Tam. (2022) Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma. Asia-Pacific Journal of Clinical Oncology 19:1, pages 87-95.
Crossref
Edward B. Garon, Patrick Peterson, Maria Teresa Rizzo & Jong Seok Kim. (2022) Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non–Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies. Clinical Lung Cancer 23:3, pages 253-263.
Crossref
Yoon Jung Jang, Dong-gon Hyun, Chang-Min Choi, Dae Ho Lee, Sang-We Kim, Shinkyo Yoon, Woo Sung Kim, Wonjun Ji & Jae Cheol Lee. (2021) Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. BMC Cancer 21:1.
Crossref
Wang Chun Kwok, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip & Terence Chi Chun Tam. (2021) Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung. Lung Cancer 162, pages 169-174.
Crossref
Andrea Spini, Giulia Hyeraci, Claudia Bartolini, Sandra Donnini, Pietro Rosellini, Rosa Gini, Marina Ziche, Francesco Salvo & Giuseppe Roberto. (2021) Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data. International Journal of Environmental Research and Public Health 18:14, pages 7679.
Crossref
Xin Li, Jie Huang, Yao Qiu, Qianyun Zhang, Shaoyu Yang, Kan Wu, Jiaoli Wang, Limin Wang, Jian Ye, Shenglin Ma, Bing Xia & Xueqin Chen. (2021) Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study. Frontiers in Pharmacology 12.
Crossref
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip & Terence Chi Chun Tam. (2021) Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid. Lung Cancer 152, pages 15-20.
Crossref
Long-Hua Guo, Ming-Feng Zhang, He-Long Zhang, Jian-Ying Zhou, Xiao-Hong Cai, Yu Long, Qi-Sen Guo, Nong Yang, Jun Zhao, Zhan-Hong Xie, Bo Jiang, Ying Zhu, Yun Fan, Cong-Ying Xie, Yi Hu, Yu Yao, Jun Jia, Xiao-Ling Li, Jiu-Wei Cui, Xi-Zhao Sui, Wen Lin, Ying Cheng, Hui-Juan Wang, Chang-Li Wang, Ming-Fang Zhao, Gui-Bin Qiao, Li-Jun Peng, Lin Yang, Gong-Yan Chen, Kai-Can Cai, Xin-Hua Xu, Liang-Ming Zhang, Guo-Sheng Feng, Jing-Min Zhou, Guo-Wu Wu, Xiao-Rong Dong, Li-Feng Wang, Hong-Mei Zhang, Ya-Jie Gao, Qiu-Ying Jiang, Shun-Dong Cang, Zhi-Xiong Yang, Xia Song, Xiao-Qing Liu, Bo Zhu, Feng-Xia Chen, Chun-Hong Hu, Xi Chen, Yi-Long Wu & Qing Zhou. (2020) Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma. Frontiers in Oncology 10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.